Osteomalacia natural history, complications and prognosis
|
Osteomalacia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Osteomalacia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Osteomalacia natural history, complications and prognosis |
|
FDA on Osteomalacia natural history, complications and prognosis |
|
CDC on Osteomalacia natural history, complications and prognosis |
|
Osteomalacia natural history, complications and prognosis in the news |
|
Blogs on Osteomalacia natural history, complications and prognosis |
|
Risk calculators and risk factors for Osteomalacia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Ibrahim Elkhayat, M.B.B.Ch.[3]
Osteomalacia generally evolves gradually from a biochemical and histologic mineralization defect to symptomatic skeletal and neuromuscular disease. In severe or prolonged disease, mechanically weak bone may develop pseudofractures, fractures, and skeletal deformity. The prognosis is generally favorable when the underlying cause is identified and corrected, although recovery of bone mass and skeletal microarchitecture may lag behind biochemical and symptomatic improvement.[1][2][3]
Natural history
Osteomalacia may remain clinically and radiographically occult during its early stages. In nutritional osteomalacia, compensatory secondary hyperparathyroidism and increased bone turnover may precede overt hypocalcemia or hypophosphatemia. Histologic abnormalities of osteoid accumulation and delayed mineralization may therefore precede characteristic abnormalities on plain radiographs.[1][2][3]
The subsequent clinical course may include:
- Early/occult disease: Biochemical and histologic abnormalities without characteristic radiographic findings.
- Symptomatic disease: Progressive diffuse bone pain and tenderness, fatigue, and proximal muscle weakness with functional limitation and gait disturbance. Because these manifestations are nonspecific, osteomalacia may be mistaken for rheumatologic, neuromuscular, or other pain disorders.[4]
- Advanced disease: Severe or prolonged mineralization defects may result in Looser zones (pseudofractures), pathological fractures, vertebral deformity, and other skeletal abnormalities.[5][3]
In phosphopenic osteomalacia, including tumor-induced osteomalacia (TIO) and hereditary hypophosphatemic disorders, persistent renal phosphate wasting produces chronic hypophosphatemia and defective mineralization. Untreated TIO may progressively increase skeletal morbidity, particularly when diagnosis is delayed.[6][7]
Diagnostic delay is an important contributor to skeletal morbidity in TIO. Reported delays from symptom onset to diagnosis may extend for several years, with substantial variation between patients, allowing potentially irreversible skeletal damage to accumulate.[7]
Complications
Skeletal complications
The principal complications result from reduced mineralization and impaired mechanical strength of bone.
- Fragility and pathological fractures: Fractures may occur with minimal or no trauma and can involve the ribs, vertebrae, pelvis, and long bones. Patients with TIO may develop multiple fractures.[5][8]
- Looser zones (pseudofractures): These incomplete fractures are characteristic of severe osteomalacia and may occur at the femoral neck, femoral shaft, pubic rami, ribs, scapula, clavicle, ulna, and metatarsals.[5][3]
- Skeletal deformity: Long-standing severe disease may produce bowing of long bones, vertebral concavity (codfish vertebrae), and other structural deformities.[5][3]
- Low or abnormal bone mineral density: DXA may demonstrate reduced BMD, but BMD findings are variable and do not establish or exclude osteomalacia. Normal or relatively high BMD can occur in some phosphopenic disorders, including XLH.[3]
Neuromuscular and functional complications
Proximal muscle weakness may cause difficulty rising from a chair, climbing stairs, or walking and may produce a waddling gait. Severe pain, weakness, and fractures can result in substantial functional limitation and impaired quality of life.[4][9]
In severe calcipenic disease, hypocalcemia may produce neuromuscular irritability, tetany, or seizures. QT prolongation may occur with significant hypocalcemia. Severe deficiency in infancy within the rickets–osteomalacia spectrum may rarely be complicated by dilated cardiomyopathy and heart failure.[1]
Functional disability and quality of life
Chronic skeletal pain, fractures, proximal myopathy, and skeletal deformity may progressively impair mobility and quality of life. In TIO, prolonged phosphate wasting and diagnostic delay may result in substantial and potentially persistent musculoskeletal disability.[8][7]
Prognosis after treatment
Osteomalacia is generally a highly reversible metabolic bone disorder when the underlying cause is recognized and corrected. Biochemical and clinical recovery commonly precede complete recovery of bone mass and skeletal microarchitecture.[1][10]
Nutritional and calcipenic osteomalacia
Correction of vitamin D and calcium deficiency generally improves biochemical abnormalities, bone pain, and muscle weakness and reduces ongoing skeletal morbidity. Recovery occurs over weeks to months, although the duration depends on disease severity, duration, and the underlying cause.[1][10]
Long-standing disease may leave residual skeletal deformity or fracture-related disability despite correction of the mineralization defect.[3][10]
Tumor-induced osteomalacia
Complete resection of a causative phosphaturic mesenchymal tumor is typically curative. Intact FGF23 generally normalizes within approximately 24 hours, and serum phosphate typically normalizes within approximately 5 days; in a large postoperative cohort, normalization occurred within 7 days in approximately 83% of cured patients. Alkaline phosphatase and skeletal mineralization recover more gradually, with skeletal healing potentially continuing for approximately 1 year.[11][12][13]
Hungry bone syndrome may occur after successful TIO tumor resection during rapid skeletal remineralization. It is characterized by secondary hyperparathyroidism with variable hypocalcemia, hypophosphatemia, and hypomagnesemia and may require calcium and vitamin D supplementation during the postoperative period.[11]
Bone mineral density can improve substantially after successful treatment, particularly at the spine and hip, although recovery at peripheral skeletal sites may be slower. Long-standing fractures, vertebral deformities, and other structural damage may not completely reverse.[8][12]
Persistent or recurrent TIO remains an important prognostic concern. In a large review, initial surgery was successful in approximately 59% of patients and overall successful resection was approximately 67%; these estimates include patients in whom the tumor could not necessarily be localized or completely resected. By contrast, a systematic review of more than 1,725 cases reported surgery to be successful in more than 90% of patients in whom the causative tumor was localized, illustrating the importance of the denominator used when reporting surgical success.[14][15]
In a 230-patient cohort, approximately 18% had refractory disease, defined by nonremission or recurrence, with a median time to recurrence of approximately 33 months.[16]
Bone-derived tumors, spinal location, malignant histology, lower preoperative serum phosphate, and higher preoperative FGF23 have been associated with a less favorable course.[16][11][12]
In a retrospective cohort, non-localizing TIO was associated with significantly lower survival than localizing disease. An FGF23 level greater than 20 times the upper limit of normal in the presence of normal renal function, together with recurrence after initial cure, was associated with malignancy.[17]
For nonlocalizable, unresectable, or recurrent TIO, conventional therapy with oral phosphate plus active vitamin D and burosumab, an anti-FGF23 monoclonal antibody, can improve phosphate homeostasis and osteomalacia-related manifestations. Detailed dosing and monitoring are addressed in the Medical therapy microchapter.[11][18]
Prognostic considerations
| Clinical feature | Prognostic significance |
|---|---|
| Cause identified and corrected | Generally favorable; biochemical and symptomatic recovery is expected |
| Long-standing untreated disease | Greater risk of fractures, deformity, and persistent functional impairment |
| Severe skeletal involvement | Recovery may be prolonged, with possible residual structural damage |
| Successful TIO tumor resection | Usually followed by rapid biochemical improvement and progressive skeletal recovery |
| Persistent or recurrent TIO | Requires ongoing surveillance and may result in prolonged skeletal morbidity |
| Non-localizing or unresectable TIO | Less favorable course and need for long-term medical management |
| Malignant TIO | Less favorable prognosis and requires long-term oncologic/endocrine follow-up |
Clinical implications
- The prognosis of osteomalacia depends primarily on identifying and correcting the underlying mineralization defect rather than on the BMD value at diagnosis.[3]
- Biochemical and symptomatic recovery may occur before complete skeletal recovery; patients with severe or long-standing disease may therefore require prolonged follow-up.[10][8]
- After successful TIO resection, early postoperative changes in phosphate and calcium metabolism should be recognized, including possible hungry bone syndrome.[11]
- Patients treated for TIO require long-term surveillance for persistent or recurrent phosphate wasting, particularly when complete tumor resection is not achieved.[11][16]
Uncertainties and evidence limitations
The true population burden and long-term prognosis of nutritional osteomalacia remain incompletely defined because the disease is frequently underrecognized.[2]
The extent to which structural skeletal damage and quality-of-life impairment are completely reversible after prolonged TIO remains incompletely characterized, particularly in patients with longstanding fractures or deformity.[8][12]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Uday S; Högler W (2020). "Nutritional Rickets & Osteomalacia: A Practical Approach to Management". Indian Journal of Medical Research. 152 (4): 356–367. doi:10.4103/ijmr.IJMR_1961_19.
- ↑ 2.0 2.1 2.2 Uday S; Högler W (2019). "Spot the Silent Sufferers: A Call for Clinical Diagnostic Criteria for Solar and Nutritional Osteomalacia". Journal of Steroid Biochemistry and Molecular Biology. 188: 141–146. doi:10.1016/j.jsbmb.2019.01.004.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Jha S; Chapman M; Roszko K (2019). "When Low Bone Mineral Density and Fractures Is Not Osteoporosis". Current Osteoporosis Reports. 17 (5): 324–332. doi:10.1007/s11914-019-00529-7.
- ↑ 4.0 4.1 Abi-Ghanem AS; Chouairy CJ; Meguerian Z; Azar L (2020). "A 49-Year-Old Man With Debilitating Aches and Pains and a Mysterious Culprit". Arthritis Care & Research. 72 (1): 1–8. doi:10.1002/acr.23807.
- ↑ 5.0 5.1 5.2 5.3 Sam A; Meeran K; Hill N (2023). Osteomalacia. Endocrinology and Diabetes.
- ↑ Brandi ML; Clunie GPR; Houillier P; et al. (2021). "Challenges in the Management of Tumor-Induced Osteomalacia (TIO)". Bone. 152: 116064. doi:10.1016/j.bone.2021.116064.
- ↑ 7.0 7.1 7.2 Crotti C; Bartoli F; Coletto LA; et al. (2021). "Tumor Induced Osteomalacia: A Single Center Experience on 17 Patients". Bone. 152: 116077. doi:10.1016/j.bone.2021.116077.
- ↑ 8.0 8.1 8.2 8.3 8.4 Minisola S; Colangelo L; Pepe J; Cipriani C; Corsi A (2025). "Skeletal Involvement in Tumor-Induced Osteomalacia". Journal of Bone and Mineral Research. doi:10.1093/jbmr/zjaf148.
- ↑ Kim SW; Hong N; Rhee Y; et al. (2018). "Clinical and Laboratory Features of Patients With Osteomalacia Initially Presenting With Neurological Manifestations". Osteoporosis International. 29 (7): 1617–1626. doi:10.1007/s00198-018-4501-1.
- ↑ 10.0 10.1 10.2 10.3 Slouma M; Bettaieb H; Rahmouni S; Cheour E; Lamloum M (2026). "Personalized Treatment Pathways for Adult Osteomalacia". Journal of Clinical Densitometry. 29 (2): 101685. doi:10.1016/j.jocd.2026.101685.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 Jan de Beur SM; Minisola S; Xia WB; et al. (2023). "Global guidance for the recognition, diagnosis, and management of tumour-induced osteomalacia". Journal of Internal Medicine. 293 (3): 309–328. doi:10.1111/joim.13593. PMID 36609775 Check
|pmid=value (help). - ↑ 12.0 12.1 12.2 12.3 Shan C; Wei Z; Li S; et al. (2025). "Postoperative Outcome and Clinical Management of Tumor-Induced Osteomalacia: A Single-Center Retrospective Cohort Study on 117 Patients". Osteoporosis International. doi:10.1007/s00198-025-07527-9. PMID 40493241 Check
|pmid=value (help). - ↑ Minisola S; Peacock M; Fukumoto S; et al. (2017). "Tumour-induced osteomalacia". Nature Reviews Disease Primers. 3: 17044. doi:10.1038/nrdp.2017.44.
- ↑ Jan de Beur SM; Dahir KM; Imel EA; et al. (2024). "Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review". The Journal of Clinical Endocrinology and Metabolism. 110 (1): 102–113. doi:10.1210/clinem/dgae431.
- ↑ Rendina D; Abate V; Cacace G; et al. (2022). "Tumor-Induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis". The Journal of Clinical Endocrinology and Metabolism. 107 (8): e3428–e3436. doi:10.1210/clinem/dgac253.
- ↑ 16.0 16.1 16.2 Li X; Jiang Y; Huo L; et al. (2020). "Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study". Journal of Bone and Mineral Research. 35 (3): 469–477. doi:10.1002/jbmr.3903.
- ↑ Hoong CWS; Sfeir J; Algeciras-Schimnich A; Clarke BL (2025). "A Retrospective Cohort of Tumor-Induced Osteomalacia and Case Series of Malignant Disease". The Journal of Clinical Endocrinology and Metabolism. 110 (2): e397–e411. doi:10.1210/clinem/dgae183. PMID 38506445 Check
|pmid=value (help). - ↑ Rodrigues CG; de Oliveira CT; de Lima IF; et al. (2026). "Efficacy and Safety of Burosumab in Tumor-Induced Osteomalacia: A Systematic Review and Meta-Analysis". Bone. 208: 117888. doi:10.1016/j.bone.2026.117888. PMID 41951116 Check
|pmid=value (help).